eli lilly glp-1 stock analysis Outlook Has 140% Upside Amid Drug Growth: Goldman 🚨 A trillion-dollar moment in

The experts I spoke to said the potential connection between anhedonia and GLP-1 needs further study

Net cost differences were AU$4.2 billion for SGLT2is and AU$20.2 billion for GLP-1 RAs, and the ICERs were AU$23,717 and AU$100,705 per QALY gained, respectively

Tolerability though safe and taken by millions of people, GLP-1s still leave more to be desired from tolerability with troublesome gastrointestinal side effects

Access this article Similar content being viewed by others References Kaiser AB, Zhang N, Der Pluijm WV

A 2024 double-blind randomized trial of 156 participants with early Parkinsons disease found that participants receiving a GLP-1 drug, lixisenatide, showed no progression of motor symptoms, compared to a measurable worsening on standard motor scales in the placebo group